Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus granulosus | jun protein | 0.0097 | 1 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0041 | 0.3091 | 0.5 |
Echinococcus multilocularis | jun protein | 0.0097 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.3091 | 0.3996 |
Schistosoma mansoni | hypothetical protein | 0.0079 | 0.7736 | 1 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription | 0.0041 | 0.3091 | 0.3091 |
Schistosoma mansoni | jun-related protein | 0.0079 | 0.7736 | 1 |
Entamoeba histolytica | hypothetical protein | 0.0041 | 0.3091 | 0.5 |
Echinococcus multilocularis | Basic leucine zipper (bZIP) transcription factor | 0.0097 | 1 | 1 |
Schistosoma mansoni | transcription factor LCR-F1 | 0.0041 | 0.3091 | 0.3996 |
Echinococcus granulosus | nuclear factor of activated T cells 5 | 0.0085 | 0.8512 | 0.8512 |
Brugia malayi | hypothetical protein | 0.0076 | 0.7404 | 0.6243 |
Echinococcus multilocularis | nuclear factor of activated T cells 5 | 0.0085 | 0.8512 | 0.8512 |
Entamoeba histolytica | hypothetical protein | 0.0041 | 0.3091 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0041 | 0.3091 | 0.5 |
Onchocerca volvulus | 0.0076 | 0.7404 | 0.5 | |
Echinococcus granulosus | Basic leucine zipper bZIP transcription factor | 0.0097 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0094 | 0.9669 | 1 |
Echinococcus granulosus | Basic leucine zipper bZIP transcription | 0.0041 | 0.3091 | 0.3091 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
EC50 (functional) | = 190 uM | Ex vivo immunosuppressive activity in Drosophila larvae assessed as inhibition of IMD signaling pathway by beta-galactosidase reporter gene assay | ChEMBL. | 21334120 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.